Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Alterity Therapeutics Ltd ABN/ARBN Financial year ended: 37 080 699 065 30 June 2026 ...
Appendix 4G
Filed with ASX · · 12 pages · English
On 6ix: 6ix.com/news/appendix-4g-55
Release
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Application for quotation of securities - ATH
- Disclosure Under Takeovers Panel GN 20
- Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
- Granted New U.S. Composition of Matter Patent for ATH434
- Alterity to Present at Canaccord Genuity Growth Conference
Later from Alterity Therapeutics
- Corporate Governance Statement
- Appendix 4E and 2026 Annual Report
- $4.2M Options Underwriting Agreement Executed
- Alterity Therapeutics Filed Form 20-F and XBRL Data with SEC
- Change of Director's Interest Notice - Marks
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics